Literature DB >> 24802235

Xihuang Pill () induces mesenchymal-epithelial transition and inhibits loss of apical-basal polarity in colorectal cancer cell through regulating ZEB1-SCRIB loop.

Miao Wang1, Jing-yan Meng, Su-fei He.   

Abstract

OBJECTIVE: To investigate the antiproliferative and anti-metastasis effect of Xihuang Pill (, XP) on human colorectal cancer cell and to explore the molecular mechanism by which it produces the effects.
METHODS: Highly metastatic human colorectal cancer cell line LoVo was treated with low-, medium-, and highdose XP-containing serum (XP-L, XP-M, XP-H) groups for 48 h, cells intervened with no drug rat serum and PD98059 [extracellular signal-regulated kinase (ERK) inhibitor] as negative and positive controls (NC and PC) groups. Cell proliferation assay was made using cell counting kit-8 (CCK8). The 8 μm pore-size transwell chamber and 4', 6-diamidino-2-phenylindole (DAPI) staining were applied to examine the ability of invasion and migration of the cells. The protein expression of ERK1/2, zinc fifi nger E-box-binding homeobox 1 (ZEB1), Scrib and lethal giant larvae homolog 2 (Lgl2) was detected by Western blotting while the relative mRNA quantity of E-cadherin, N-cadherin, Occludin and junctional adhesion molecule-1 (JAM1) was measured by realtime fluorescent quantitative polymerase chain reaction (RT-qPCR).
RESULTS: XP induced a dose-dependent suppression on the proliferation of LoVo cells (P <0.05 or P<0.01), with the inhibition rates varied from 27.30% to 31.08%. Transwell assay showed that when preprocessed with PD98059 and XP-containing serum, the number of cells that passed the filter decreased significantly compared with that of NC group (P <0.05 or P<0.01). Moreover, XP inhibited the protein expression of ERK1/2 and ZEB1 (P <0.05); and up-regulated the protein expression of Scrib and Lgl2 (P <0.05). The mRNA levels of E-cadherin, Occludin and JAM1 of the XP intervened groups and PC group markedly ascended (P <0.05) while that of N-cadherin showed a descending tendency (P>0.05).
CONCLUSION: XP intervention suppressed the ability of proliferation, invasion and migration of the LoVo cells. Regulating ZEB1-SCRIB Loop so as to recover epithelial phenotype and apical junctional complex might be one of the mechanisms by which XP produces the anti-metastasis effect.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24802235     DOI: 10.1007/s11655-014-1812-8

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  24 in total

1.  ERK2/Fra1/ZEB pathway induces epithelial-to-mesenchymal transition.

Authors:  Sejeong Shin; John Blenis
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

2.  The cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction.

Authors:  K Nagasaka; D Pim; P Massimi; M Thomas; V Tomaić; V K Subbaiah; C Kranjec; S Nakagawa; T Yano; Y Taketani; M Myers; L Banks
Journal:  Oncogene       Date:  2010-07-12       Impact factor: 9.867

Review 3.  Epithelial organization, cell polarity and tumorigenesis.

Authors:  Luke Martin McCaffrey; Ian G Macara
Journal:  Trends Cell Biol       Date:  2011-07-21       Impact factor: 20.808

4.  ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1.

Authors:  E Sánchez-Tilló; A Lázaro; R Torrent; M Cuatrecasas; E C Vaquero; A Castells; P Engel; A Postigo
Journal:  Oncogene       Date:  2010-04-26       Impact factor: 9.867

Review 5.  Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer.

Authors:  Ralph A Neumüller; Juergen A Knoblich
Journal:  Genes Dev       Date:  2009-12-01       Impact factor: 11.361

Review 6.  Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.

Authors:  Ajay Kumar Chaudhary; Shruti Pandya; Kanjaksha Ghosh; Anita Nadkarni
Journal:  Mutat Res       Date:  2013-01-28       Impact factor: 2.433

Review 7.  ERK1/2 MAP kinases: structure, function, and regulation.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2012-04-27       Impact factor: 7.658

8.  Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Fazlul H Sarkar
Journal:  Cancers (Basel)       Date:  2011-02-21       Impact factor: 6.639

Review 9.  Epithelial cell polarity: a major gatekeeper against cancer?

Authors:  C Royer; X Lu
Journal:  Cell Death Differ       Date:  2011-05-27       Impact factor: 15.828

Review 10.  Cell adhesion and its endocytic regulation in cell migration during neural development and cancer metastasis.

Authors:  Takeshi Kawauchi
Journal:  Int J Mol Sci       Date:  2012-04-11       Impact factor: 6.208

View more
  4 in total

Review 1.  Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor Treatment.

Authors:  Qiujun Guo; Jinyin Lin; Rui Liu; Yebo Gao; Shulin He; Xinyao Xu; Baojin Hua; Conghuang Li; Wei Hou; Honggang Zheng; Yanju Bao
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-10       Impact factor: 2.629

2.  Clinical Effects of Xihuang Pill Combined with Chemotherapy in Patients with Advanced Colorectal Cancer.

Authors:  Dan Yu; Guang Yu An
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-28       Impact factor: 2.629

3.  Antitumor effects of Xi Huang pills on MDA‑MB‑231 cells in vitro and in vivo.

Authors:  Wenxian Zheng; Shuyan Han; Shantong Jiang; Xiran He; Xiaohong Li; Huirong Ding; Minhua Cao; Pingping Li
Journal:  Mol Med Rep       Date:  2018-06-21       Impact factor: 2.952

4.  Xihuang Pill Induces Apoptosis of Human Glioblastoma U-87 MG Cells via Targeting ROS-Mediated Akt/mTOR/FOXO1 Pathway.

Authors:  Meng Shao; Zhenqiang He; Zhixin Yin; Peihong Ma; Qian Xiao; Yafeng Song; Ziming Huang; Yujie Ma; Yuqin Qiu; Aizhi Zhao; Taicheng Zhou; Qirui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-26       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.